Preferred Pharmaceuticals Lidocaine Ointment
Lidocaine Ointment USP, 5% failed content uniformity specifications.
Moderate risk
Taking it may cause temporary or medically reversible health problems. Serious harm is unlikely.
FDA Class II recall · How risk is rated
What happened
Preferred Pharmaceuticals, Inc. recalled Lidocaine Ointment USP, 5% (Generic for Xylocaine), packaged in a 50 g jar, Rx only, manufactured by Taro Pharmaceuticals U.S.A., Inc., because it failed content uniformity specifications. The recall began September 28, 2026, and was added to the FDA's Enforcement Report on October 6, 2026.
Summary by Recall Canary from the FDA notice.
What to do
We don't have product-specific instructions for this recall. FDA's general advice for medicine recalls:
- Check the FDA or company notice for instructions specific to this product.
- Ask your pharmacist or doctor whether your lot is affected and what to do.
Is yours affected?
Match the NDC and lot code listed under your product.
Lidocaine Ointment USP, 5%
- NDC
- 68788-7865-05
- Lot
- F1925G
- E0925T
- D3025M
- D0825D
Details
- Company began the recall
- Event ID
- 99994
- Company
- Preferred Pharmaceuticals, Inc.
- Hazard
- Failed specifications
Company began the recall
Added to FDA's Enforcement Report · Classified by FDA
Listed on Recall Canary
In FDA's weekly enforcement report
